Navigation Links
Sanofi-aventis Stands Behind the Safety of Lantus(R)
Date:6/26/2009

nded by the ADA. The HbA1c test measures average blood glucose levels over the past two- to three-month period.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include product development, product potential projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including po
'/>"/>

SOURCE sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
2. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
3. Kibow Biotech Obtains Australian, Chinese and Indian Patents Protecting the Composition and Basic Technology Behind Its Oral Probiotic Formulation for Chronic Kidney Failure
4. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
5. New Safety Regulations Drive Greater Need for Resources and Expertise at Every Stage of Clinical Development
6. Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily
7. AFRESA(R) Phase 3 Pulmonary Function Safety Data in Patients with Diabetes Presented at ADA
8. Researchers Present Safety and Efficacy Results of 429 Patients Treated With Radiofrequency Ablation for Pre-Cancerous Barretts Esophagus
9. Living Donor Kidney Transplants Using Alemtuzumab Pre-Conditioning and Tacrolimus Monotherapy: Long-Term Safety and Efficacy
10. Results and Additional Analyses From Efficacy and Safety Study of Cortheras Relaxin in Acute Heart Failure to be Presented at Heart Failure Congress 2009
11. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)... , Another option to prevent illnesses..., SILVER SPRING, Md., Nov. 27 /PRNewswire-USNewswi... approved Agriflu for people ages 18 years and old...btypes A and B. ,, (Logo: http://www.newscom..., manufactured by Novartis Vaccines and Diagnostic...
(Date:11/27/2009)... , BLOOMINGTON, Minn, Nov. 27 ... medical image management software, data migration...he United States Patent and Trademark Office has a...cation Format within a Computer Network." Acuo Tec... portfolio of intellectual property. In general, t...
(Date:11/26/2009)... , JOHANNESBURG, South Africa, Nov. 26 /... Africa Company of the Year Award in the Generic P...South Africa Limited. ,, (Logo: http://www.new...the Company of the Year Award, the following crite...nce against key competitors: growth strategy and i...
Breaking Medicine Technology:FDA Approves Agriflu Seasonal Influenza Vaccine 2Acuo Technologies Announces Patent for Asset Communication Format Within a Computer Network 2Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 2Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 3Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 4Pharma Marketer com 3A One Stop Pharmaceutical Marketing Resource 51253 1Pharma Marketer com 3A One Stop Pharmaceutical Marketing Resource 51253 2AACR applauds nomination of Francis S Collins M D Ph D to be the new NIH director 9195 1University of Phoenix Expands Advanced Degree Programs 3B Adds Ph D in Nursing and Educational Specialist Degrees 51246 1University of Phoenix Expands Advanced Degree Programs 3B Adds Ph D in Nursing and Educational Specialist Degrees 51246 2University of Phoenix Expands Advanced Degree Programs 3B Adds Ph D in Nursing and Educational Specialist Degrees 51246 3
...xplorations to support bold, unconventio...March 3 The Bill & Melinda Gates Foundation,annou...accept grant,proposals for the first funding round...llion initiative to help scientists across the glo... for solving major health problems.,The four topic...
..., a Research Management,Organization (RMO), has co...iary of Seattle-based Cell Therapeutics, Inc. (CTI...s for their phase II open-label,clinical study for...ranslocation. The study is intended to assess the ...duct, brostallicin. The trial will also be,support...
Other Medicine Technology:Gates Foundation Seeks Proposals for Innovative Global Health Research 2Gates Foundation Seeks Proposals for Innovative Global Health Research 3Pharmatech Teams up With Systems Medicine LLC and the Sarcoma Foundation of America for a Phase II Myxoid Liposarcoma Trial 2Pharmatech Teams up With Systems Medicine LLC and the Sarcoma Foundation of America for a Phase II Myxoid Liposarcoma Trial 3
(Date:11/28/2009)...pirits, recognize signs of depression , ,...eniors, the holiday season can trigger melancholy ... health issues or worry about money problems, acco...help overcome the seasonal blues, the AGS Foundati...: , Get out and socialize or invite family and f...
(Date:11/27/2009)...PRNewswire/ - Uploadable USB pedometers may be new...s. A combination of advanced accelerometer functio...g term concern over the accuracy of self-reported ...ward improved participation in a fitness program. ...wellness suppliers to integrate this technology. "...
(Date:11/27/2009)...wswire-USNewswire/ -- Considered a highly risky an...o, solid organ transplantation is now a life-savin... men and women who gathered at the Winspear Opera ...from medical centers around the world to celebrate...t Institute (BRTI), one of the pioneers of solid o...
(Date:11/27/2009)... 27 Preventing disease ...unately every year, new vaccines are being added t...s boost immunity for the same period of time? And,...d to keep immunity strong? ,, In this month,s...Academy of Pediatrics, Michael Pichichero MD, Dire...
(Date:11/27/2009)..., Nov. 27 Shamir Optical...ading provider of innovative products and technolo...that its board of directors had declared a dividen...llion (approximately NIS 37.62 million based on th...e), or approximately US$ 0.609 (approximately NIS ...
Breaking Medicine News(10 mins):Health News:Seniors May Need Help Overcoming Holiday Blues 2Health News:New USB technology adds accountability and convenience to wellness programs 2Health News:Organ Transplant Pioneers Celebrate Baylor Regional Transplant Institute's 25th Anniversary 2Health News:Organ Transplant Pioneers Celebrate Baylor Regional Transplant Institute's 25th Anniversary 3Health News:Why Some Vaccines May Require A Booster 2Health News:Why Some Vaccines May Require A Booster 3Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 2Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 3
... the new 30" in groundbreaking new calendar , , H...the island,s first au natural calendar to promote ... The 51-year-old native Chamorrita is beautifully ...e. "I wanted to show that women of all ages can ta...
...ectations , , Higher Employee Healthcare Costs Im...27 Air Methods Corporation (Nasdaq: AIRM ), the... world, provided an update on fourth quarter 2008 ...for community bases in operation greater than one ...
...ough Corporation (NYSE: SGP ) today reported tha...revir HCV SPRINT-2 study, a pivotal Phase III stud...CV RESPOND-2 study, a pivotal Phase III study in p... its lead investigational oral hepatitis C proteas...
...nc. (Nasdaq: OSTE ), a leader in the emerging ...ng, announced today that it has appointed two expe... newly created roles of Senior Vice President of S...ring to market innovative, therapy-driven products...
... market complexity and significant barriers to ent...s and topical hemostats markets. However, the incr...gy innovations are continuing to drive growth. Rea... Sullivan ( http://www.medicaldevices.frost.com ),...
...ical and surgical equipment supplier, DRE adds aff...ital beds to its extensive product lineup. , ...RE Medical Equipment — named by Business Fir...economically-priced hospital beds includes the Hil...
Other Medicine News:Health News:Air Methods Provides 4th Quarter Update 2Health News:Air Methods Provides 4th Quarter Update 3Health News:Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients 2Health News:Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients 3Health News:Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients 4Health News:Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients 5Health News:Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients 6Health News:Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients 7Health News:Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients 8Health News:Osteotech Expands Senior Management Team; New Executives to Drive Sales Force Strategies and Therapy-Based Solutions 2Health News:Osteotech Expands Senior Management Team; New Executives to Drive Sales Force Strategies and Therapy-Based Solutions 3Health News:Osteotech Expands Senior Management Team; New Executives to Drive Sales Force Strategies and Therapy-Based Solutions 4Health News:Ready-To-Use Products Spur the European Tissue Sealants and Topical Hemostats Markets, Says Frost & Sullivan 2Health News:Ready-To-Use Products Spur the European Tissue Sealants and Topical Hemostats Markets, Says Frost & Sullivan 3Health News:DRE Medical Equipment Now Sells Reconditioned Hill-Rom Hospital Beds 2Health News:DRE Medical Equipment Now Sells Reconditioned Hill-Rom Hospital Beds 3
Troutman Punch Piston, 5.0 - 7.0mm
Troutman Punch Piston, 7.0 - 9.0mm
1.5mm Oval Cupped Intraocular Forceps
Retinal Scissors (20 Ga Titanium)
Medicine Products: